Developer docs
API playgroundTry for free, no card

Search company profiles

Eolo Pharma

Full company profile

uuid0000bli

Namestring
Eolo Pharma
Legal namestring
EoloPharma
Websiteurl
eolo-pharma.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Eolo Pharma is a clinical-stage biotechnology company headquartered in Montevideo, Uruguay, and incorporated in Delaware, USA, developing first-in-class small molecule therapeutics for obesity and metabolic diseases. The company's lead compound, SANA (also known as MVD1), is an orally administered salicylic acid nitroalkene derivative that activates creatine-dependent thermogenesis — a newly validated mechanism that increases resting energy expenditure through enhanced mitochondrial respiration and fat oxidation, functioning independently of UCP1 and AMPK pathways. SANA has completed Phase 1a/b trials in Australia, with peer-reviewed results published in Nature Metabolism in June 2025 demonstrating approximately 3% weight loss after two weeks, improved fasting glucose and insulin resistance, and no serious adverse events. The company plans to initiate Phase 2 trials in 2025 as both standalone therapy and in combination with GLP-1 drugs.

The broader pipeline comprises 60 novel chemical entities (NCEs) across indications including obesity, Type 2 diabetes, NASH, hypertension, ALS, and Alzheimer's disease, with additional candidates such as Eolo40 (NF-kB inhibitor) and an MVD1 analog. Eolo Pharma operates a research-driven model with deep integration to Institut Pasteur de Montevideo (where the CMO serves as Head) and Universidad de La República, leveraging Uruguayan academic infrastructure for preclinical and clinical research. The board includes obesity medicine leaders (Fatima Cody Stanford, Arne Astrup) and biotech operators with prior exits and large-pharma backgrounds. The company is privately held and pre-revenue, having raised approximately $4.5M across two disclosed funding rounds (2020 and 2023), with revenue expected upon regulatory approval of pipeline assets.

Short descriptiontext

Eolo Pharma is a clinical-stage biotechnology company developing SANA/MVD1, a first-in-class oral small molecule that activates creatine-dependent thermogenesis for obesity and metabolic disease treatment. Founded 2017, headquartered in Uruguay, pre-revenue with Phase 1 results published in Nature Metabolism.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
obesity therapeutics, metabolic disease drugs, small molecule pharmaceuticals, clinical-stage biotechnology, creatine-dependent thermogenesis
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Obesity and Metabolic Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Revenue expected to come from pharmaceutical product sales upon regulatory approval of SANA/MVD1 and other pipeline compounds for obesity and metabolic disease treatment.

eolo-pharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Eolo Pharma is a clinical-stage biotechnology company developing a pipeline of first-in-class, orally administered small molecule therapeutics (lead candidate SANA/MVD1) that target creatine-dependent thermogenesis to treat obesity and metabolic diseases such as type 2 diabetes, NASH, and hypertension, as well as NF-kB inhibitors (Eolo40) for ALS and Alzheimer's. The company currently has no commercialized products and operates a proprietary NCE library of 60 novel molecules backed by over a decade of academic research at Institut Pasteur de Montevideo.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Approximately 3% body weight reduction after 2 weeks of highest dose treatment in Phase 1b trial
+4 more records
Product overview1 text field

Eolo Pharma is a clinical-stage biotechnology company developing a pipeline of novel chemical entity (NCE) small molecule drugs focused on obesity and metabolic disease. The core product is SANA (also referred to as MVD1), a first-in-class oral small molecule that activates creatine-dependent thermogenesis to increase energy expenditure. The company's pipeline includes 60 novel molecules, with MVD1 as the lead candidate for obesity and its comorbidities (T2 Diabetes, NASH, Hypertension). Additional candidates like Eolo40 target NF-kB inhibition for neurodegenerative diseases. Eolo Pharma is headquartered in Montevideo, Uruguay, and operates research collaborations with Institut Pasteur de Montevideo and Universidad de La República.

Product and service4 records
1SANA (Salicylic Acid Nitroalkene)
CategoryObesity and Metabolic Disease Therapeutics
Description

First-in-class, orally administered small molecule drug (salicylic acid nitroalkene) that pharmacologically activates creatine-dependent thermogenesis to increase resting energy expenditure and treat obesity and metabolic disease without suppressing appetite; functions independently of UCP1 and AMPK and is effective in thermoneutral conditions.

2MVD1
CategoryObesity and Metabolic Disease Therapeutics
Description

Lead candidate in Eolo Pharma's oral thermogenic NCE pipeline, targeting obesity and associated cardiometabolic complications (type 2 diabetes, NASH, hypertension); first-in-class small molecule that activates creatine-dependent thermogenesis and is currently in Phase 1 clinical trials.

3Eolo40
CategoryNeurodegenerative and Inflammation Therapeutics
Description

NF-kB inhibitor compound from Eolo Pharma's proprietary NCE library, being developed for potential applications in inflammation-related conditions including ALS and Alzheimer's disease where low-grade chronic inflammation is implicated.

4MVD1 Analog
CategoryObesity and Metabolic Disease Therapeutics
Description

Analog of the lead compound MVD1 within Eolo Pharma's oral thermogenic NCE library, being developed to expand the obesity and related metabolic disorder therapeutic offering.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Eolo Pharma collaborates closely with Institut Pasteur de Montevideo on research and development of small molecules for metabolic, aging, and immune diseases. The company's CMO Carlos Batthyany serves as Head of Institut Pasteur de Montevideo, facilitating deep integration between academic research and company drug development efforts.

2Universidad de La República
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with Uruguay's public university for preclinical and clinical research on obesity, diabetes, and cardiovascular diseases. Researchers from the university collaborate with Eolo's team on drug development programs.

eolo-pharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Phase 1 study being conducted in Australia with approval from a national Human Research Ethics Committee. Study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of MVD1 in healthy volunteers and overweight/obese patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing both oral and subcutaneous therapeutics for obesity and metabolic disease, including VK2735 (oral and injectable GLP-1/GIP dual agonist). Direct peer because it operates in the same clinical-stage obesity space with similar orally administered development candidates and metabolic-disease focus.

TypeDirect peer
Description

Clinical-stage company developing oral small molecule GLP-1 agonists (GSBR-1290) for obesity and type 2 diabetes. Direct peer because it competes head-to-head with Eolo in the oral, small-molecule obesity therapeutics category and is targeting similar patient segments.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing oral small molecule therapeutics for obesity (TERN-501, an oral THR-β agonist) and metabolic diseases including NASH. Direct peer because it pursues oral obesity mechanisms with similar stage and metabolic-disease indication breadth.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and metabolic disease. Direct peer because it is a similarly sized clinical-stage competitor in the obesity therapeutics space targeting body-weight reduction via novel metabolic mechanisms.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, including CagriSema in collaboration with Novo Nordisk. Direct peer because it operates in clinical-stage obesity drug development with comparable metabolic-disease pipeline breadth.

TypeBroad incumbent
Description

Global pharmaceutical leader in the obesity space with Zepbound (tirzepatide) and pipeline oral GLP-1 candidate orforglipron. Broad incumbent because it dominates the obesity therapeutics category with established commercialization that dwarfs any clinical-stage entrant.

TypeBroad incumbent
Description

Global pharmaceutical leader with Wegovy/Ozempic (semaglutide) and oral semaglutide, the dominant forces in obesity and metabolic disease therapeutics. Broad incumbent because it sets the standard of care Eolo would need to displace or complement.

TypeEmerging player
Description

Commercial-stage biopharmaceutical company focused on MASH/NASH (resmetirom, Rezdiffra), a metabolic liver disease also in Eolo's pipeline. Emerging player in adjacent metabolic indications where Eolo's NASH pipeline candidates could overlap commercially.

TypeEmerging player
Description

Clinical-stage biotechnology company developing gut-brain axis oral therapeutics for obesity and metabolic disease. Emerging player because it pursues oral, mechanism-distinct obesity treatments targeting similar unmet needs in the GLP-1-disrupted space.

TypeRegional player
Description

China-based biopharmaceutical company with mazdutide, a GLP-1/glucagon dual agonist in Phase 3 for obesity. Regional player because it operates a comparable obesity clinical-stage program primarily in the China market with limited direct competition in Eolo's geographies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eolo Pharma

Obesity and Metabolic Disease Therapeuticseolo-pharma.com

Eolo Pharma is a clinical-stage biotechnology company developing SANA/MVD1, a first-in-class oral small molecule that activates creatine-dependent thermogenesis for obesity and metabolic disease treatment. Founded 2017, headquartered in Uruguay, pre-revenue with Phase 1 results published in Nature Metabolism.

What Eolo Pharma does

Eolo Pharma is a clinical-stage biotechnology company headquartered in Montevideo, Uruguay, and incorporated in Delaware, USA, developing first-in-class small molecule therapeutics for obesity and metabolic diseases. The company's lead compound, SANA (also known as MVD1), is an orally administered salicylic acid nitroalkene derivative that activates creatine-dependent thermogenesis — a newly validated mechanism that increases resting energy expenditure through enhanced mitochondrial respiration and fat oxidation, functioning independently of UCP1 and AMPK pathways. SANA has completed Phase 1a/b trials in Australia, with peer-reviewed results published in Nature Metabolism in June 2025 demonstrating approximately 3% weight loss after two weeks, improved fasting glucose and insulin resistance, and no serious adverse events. The company plans to initiate Phase 2 trials in 2025 as both standalone therapy and in combination with GLP-1 drugs.

The broader pipeline comprises 60 novel chemical entities (NCEs) across indications including obesity, Type 2 diabetes, NASH, hypertension, ALS, and Alzheimer's disease, with additional candidates such as Eolo40 (NF-kB inhibitor) and an MVD1 analog. Eolo Pharma operates a research-driven model with deep integration to Institut Pasteur de Montevideo (where the CMO serves as Head) and Universidad de La República, leveraging Uruguayan academic infrastructure for preclinical and clinical research. The board includes obesity medicine leaders (Fatima Cody Stanford, Arne Astrup) and biotech operators with prior exits and large-pharma backgrounds. The company is privately held and pre-revenue, having raised approximately $4.5M across two disclosed funding rounds (2020 and 2023), with revenue expected upon regulatory approval of pipeline assets.

Eolo Pharma firmographics

Firmographics
Name
Eolo Pharma
Legal name
EoloPharma
Website
https://eolo-pharma.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Eolo Pharma is a clinical-stage biotechnology company developing SANA/MVD1, a first-in-class oral small molecule that activates creatine-dependent thermogenesis for obesity and metabolic disease treatment. Founded 2017, headquartered in Uruguay, pre-revenue with Phase 1 results published in Nature Metabolism.
Ownership category
akta.pro rank

Eolo Pharma industry classification

Industry
Product category
Obesity and Metabolic Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Obesity therapeutics
  • Metabolic disease drugs
  • Small molecule pharmaceuticals
  • Clinical-stage biotechnology
  • Creatine-dependent thermogenesis

Where Eolo Pharma is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Eolo Pharma business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue expected to come from pharmaceutical product sales upon regulatory approval of SANA/MVD1 and other pipeline compounds for obesity and metabolic disease treatment.

Go-to-market motion1 record

Marketing channels4 records

Eolo Pharma product offering

Product offering

Core offering

Eolo Pharma is a clinical-stage biotechnology company developing a pipeline of first-in-class, orally administered small molecule therapeutics (lead candidate SANA/MVD1) that target creatine-dependent thermogenesis to treat obesity and metabolic diseases such as type 2 diabetes, NASH, and hypertension, as well as NF-kB inhibitors (Eolo40) for ALS and Alzheimer's. The company currently has no commercialized products and operates a proprietary NCE library of 60 novel molecules backed by over a decade of academic research at Institut Pasteur de Montevideo.

Product overview

Eolo Pharma is a clinical-stage biotechnology company developing a pipeline of novel chemical entity (NCE) small molecule drugs focused on obesity and metabolic disease. The core product is SANA (also referred to as MVD1), a first-in-class oral small molecule that activates creatine-dependent thermogenesis to increase energy expenditure. The company's pipeline includes 60 novel molecules, with MVD1 as the lead candidate for obesity and its comorbidities (T2 Diabetes, NASH, Hypertension). Additional candidates like Eolo40 target NF-kB inhibition for neurodegenerative diseases. Eolo Pharma is headquartered in Montevideo, Uruguay, and operates research collaborations with Institut Pasteur de Montevideo and Universidad de La República.

Differentiator

Problem solved

Functional benefit

Products and services

  • SANA (Salicylic Acid Nitroalkene) First-in-class, orally administered small molecule drug (salicylic acid nitroalkene) that pharmacologically activates creatine-dependent thermogenesis to increase resting energy expenditure and treat obesity and metabolic disease without suppressing appetite; functions independently of UCP1 and AMPK and is effective in thermoneutral conditions.
  • MVD1 Lead candidate in Eolo Pharma's oral thermogenic NCE pipeline, targeting obesity and associated cardiometabolic complications (type 2 diabetes, NASH, hypertension); first-in-class small molecule that activates creatine-dependent thermogenesis and is currently in Phase 1 clinical trials.
  • Eolo40 NF-kB inhibitor compound from Eolo Pharma's proprietary NCE library, being developed for potential applications in inflammation-related conditions including ALS and Alzheimer's disease where low-grade chronic inflammation is implicated.
  • MVD1 Analog Analog of the lead compound MVD1 within Eolo Pharma's oral thermogenic NCE library, being developed to expand the obesity and related metabolic disorder therapeutic offering.

Quantifiable outcome

  • Approximately 3% body weight reduction after 2 weeks of highest dose treatment in Phase 1b trial
  • +4 more outcomes

Companies that use Eolo Pharma

Customer profile

Segments4 records

Ideal customer profiles1 record

Eolo Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Eolo Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Institut Pasteur de MontevideocoreStrategic or Co-development PartnerEolo Pharma collaborates closely with Institut Pasteur de Montevideo on research and development of small molecules for metabolic, aging, and immune diseases. The company's CMO Carlos Batthyany serves as Head of Institut Pasteur de Montevideo, facilitating deep integration between academic research and company drug development efforts.
  • Universidad de La RepúblicacoreStrategic or Co-development PartnerAcademic partnership with Uruguay's public university for preclinical and clinical research on obesity, diabetes, and cardiovascular diseases. Researchers from the university collaborate with Eolo's team on drug development programs.
  • Phase 1 Clinical Trial Sites (Australia)minorStrategic or Co-development PartnerPhase 1 study being conducted in Australia with approval from a national Human Research Ethics Committee. Study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of MVD1 in healthy volunteers and overweight/obese patients.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Eolo Pharma competitors and assessment

Company assessment

Direct peers

  • Viking Therapeutics: Clinical-stage biopharmaceutical company developing both oral and subcutaneous therapeutics for obesity and metabolic disease, including VK2735 (oral and injectable GLP-1/GIP dual agonist). Direct peer because it operates in the same clinical-stage obesity space with similar orally administered development candidates and metabolic-disease focus.
  • Structure Therapeutics: Clinical-stage company developing oral small molecule GLP-1 agonists (GSBR-1290) for obesity and type 2 diabetes. Direct peer because it competes head-to-head with Eolo in the oral, small-molecule obesity therapeutics category and is targeting similar patient segments.
  • Terns Pharmaceuticals: Clinical-stage biopharmaceutical company developing oral small molecule therapeutics for obesity (TERN-501, an oral THR-β agonist) and metabolic diseases including NASH. Direct peer because it pursues oral obesity mechanisms with similar stage and metabolic-disease indication breadth.
  • Altimmune: Clinical-stage biopharmaceutical company developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and metabolic disease. Direct peer because it is a similarly sized clinical-stage competitor in the obesity therapeutics space targeting body-weight reduction via novel metabolic mechanisms.
  • Zealand Pharma: Clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, including CagriSema in collaboration with Novo Nordisk. Direct peer because it operates in clinical-stage obesity drug development with comparable metabolic-disease pipeline breadth.

Broad incumbents

  • Eli Lilly and Company: Global pharmaceutical leader in the obesity space with Zepbound (tirzepatide) and pipeline oral GLP-1 candidate orforglipron. Broad incumbent because it dominates the obesity therapeutics category with established commercialization that dwarfs any clinical-stage entrant.
  • Novo Nordisk: Global pharmaceutical leader with Wegovy/Ozempic (semaglutide) and oral semaglutide, the dominant forces in obesity and metabolic disease therapeutics. Broad incumbent because it sets the standard of care Eolo would need to displace or complement.

Emerging players

  • Madrigal Pharmaceuticals: Commercial-stage biopharmaceutical company focused on MASH/NASH (resmetirom, Rezdiffra), a metabolic liver disease also in Eolo's pipeline. Emerging player in adjacent metabolic indications where Eolo's NASH pipeline candidates could overlap commercially.
  • Kallyope: Clinical-stage biotechnology company developing gut-brain axis oral therapeutics for obesity and metabolic disease. Emerging player because it pursues oral, mechanism-distinct obesity treatments targeting similar unmet needs in the GLP-1-disrupted space.

Regional players

  • Innovent Biologics: China-based biopharmaceutical company with mazdutide, a GLP-1/glucagon dual agonist in Phase 3 for obesity. Regional player because it operates a comparable obesity clinical-stage program primarily in the China market with limited direct competition in Eolo's geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Eolo Pharma social profiles

Digital presence

Eolo Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eolo Pharma leadership team

Management profile

Number of profiles

Profiles14 records

Eolo Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eolo Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eolo Pharma

What does Eolo Pharma do?

Eolo Pharma is a clinical-stage biotechnology company developing a pipeline of first-in-class, orally administered small molecule therapeutics (lead candidate SANA/MVD1) that target creatine-dependent thermogenesis to treat obesity and metabolic diseases such as type 2 diabetes, NASH, and hypertension, as well as NF-kB inhibitors (Eolo40) for ALS and Alzheimer's. The company currently has no commercialized products and operates a proprietary NCE library of 60 novel molecules backed by over a decade of academic research at Institut Pasteur de Montevideo.

Is Eolo Pharma a public or private company?

Eolo Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Eolo Pharma founded?

Eolo Pharma was founded in 2017. It employs 11 to 50 people.

Where is Eolo Pharma based?

Eolo Pharma is headquartered in San Francisco, United States, in the North America region.

How does Eolo Pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Eolo Pharma's main competitors?

Direct peers on record are Viking Therapeutics, Structure Therapeutics, Terns Pharmaceuticals, Altimmune and Zealand Pharma. Broad incumbents are Eli Lilly and Company and Novo Nordisk. Emerging players are Madrigal Pharmaceuticals and Kallyope. Innovent Biologics is listed as a regional player.

Does Eolo Pharma have an API?

No public API is recorded for Eolo Pharma.

What industry is Eolo Pharma in?

Eolo Pharma's product category is Obesity and Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaMeet The Biotech Startup Challenging Ozempic With A Fat-Burning Pill That Lets You Keep EatingEolo Pharma, a Uruguayan biotech startup, presented early human trial data for its drug candidate SANA, showing statistically significant body weight reduction compared to placebo along with improvements in fasting glucose and insulin resistance. The Phase 1a/b trial of 41 participants reported no serious adverse events, with only mild headaches and soft stools observed in some subjects. The company claims SANA is the first compound to safely activate creatine-dependent thermogenesis in humans, representing a novel mechanism distinct from GLP-1 drugs like Ozempic that suppress appetite.YahooMeet The Biotech Startup Challenging Ozempic With A Fat-Burning Pill That Lets You Keep EatingEolo Pharma's SANA pill, developed by the Uruguayan biotech startup, is reported to burn fat at rest in early human data without appetite suppression. The company says it is the first compound shown to safely activate creatine-dependent thermogenesis in humans, offering a novel approach to resetting metabolic health.ContxtoArgentine-Uruguayan, Eolo Pharma, prescribed US$2.7 million injection in Series A roundEolo Pharma, a Uruguayan-Argentine clinical research startup, raised US$2.7 million in a Series A round led by CITES and Ficus Capital. The funds will support preclinical and toxicological research on its anti-obesity drug Eolo 3, which prevented weight gain in mice on a Westernized diet. The company aims to advance to human trials.